top of page

Investor Information

Know Labs is an innovation company focused on bringing its cutting-edge developments in spectroscopy into the personal healthcare market and providing transparent quality information for the investing public and high value consumer products.

HUNDRED OF MILLIONS of people around the world suffer from diabetes and pre-diabetes. Our primary focus has been to build non-invasive continuous glucose monitors for these consumers. They are based on our proprietary Bio-RFID™ technology platform.  
KnowU and UBand will allow people with diabetes to take glucose measurements as often as they like with no fingersticks or other invasive processes. After we obtain FDA approval, they will become the world’s first non-invasive glucose monitors and clear ‘best in class’ products in a $21B+ global market.  

KnowU and UBand can also measure other molecules of value in the body that have their own large addressable markets. After a process of discovery, each ‘discovered’ molecule can be measured by the Bio-RFID sensor. Therefore, a KnowU or UBand user will be able to subscribe to multiple monthly services, some for medical reasons and others for lifestyle. 

knowlabs_marketing_kitchen_4480x2520_300ppi.jpeg

Our Goal

Know Labs is committed to furthering the science of spectroscopy so we can understand our bodies better.

This begins with a focus on the nearly 500 million people living with diabetes and 1 billion people with pre-diabetes. The Company’s goal is to provide an inexpensive entry for people with diabetes and pre-diabetes to continuously monitor their glucose levels, accompanied by a competitive monthly subscription fee compared to existing solutions. 

This is a near term goal.

Building upon its technology platform the Company plans to identify other molecules which will provide useful and life saving information to enhance the health and wellness of even more people around the world.    

As an emerging company, you want to understand and embrace the entrepreneur’s vision for the enterprise.

As an investor in Know Labs, or any technology company for that matter, transparency should be the first order of business. Keeping in mind the proprietary nature of a company’s technology, can you learn enough to make an informed decision? 

The Company has provided several videos of the bench-top prototype test results compared to FDA-cleared minimally invasive continuous glucose monitors already in the marketplace. The Company also provides access to its data in the FAQ section of its website.

The Company has detailed its Intellectual Property strategy and lists its issued patents in its annual and quarterly filings with the SEC. Current and potential investors are welcome to visit the Seattle laboratory to see the technology up close, on specified open days throughout the year. For more information about making a scheduled visit email ask@knowlabs.co


Investors considering Know Labs must be confident that the technology works and can succeed in the marketplace. You must have confidence in the leadership of the company and their commitment and capacity to achieve their stated goals. 

Management

The day-to-day leadership of the Company is managed by Chairman & CEO Ron Erickson.

Ron is a serial entrepreneur, angel investor, and attorney who has been co-founding and investing in businesses for 40 years. He has sat on scores of boards of directors, chaired audit, governance and nominating committees and provided a lifetime’s worth of strategic guidance and practical real-world experience to many companies. He played a foundational role in MicroRim, creator of the first microcomputer relational database RBase, Egghead (software retailer), eCharge (internet transaction company), DoubleDown Interactive, and more. A more detailed background on Ron, including work history, early in his career as an attorney, and in health public policy at the White House and elsewhere, can be found here

Know Labs’ senior executives are assisted in their goal to deliver the KnowU and UBand into the market by Chief Medical Officer, James “Andy” Anderson, MD. Andy is an endocrinologist specializing in diabetes and cardiometabolic disease with over 40 years experience in both clinical trials and drug/device development. He worked for 25 years with Eli Lilly and Company in global positions including Medical Leader for Diabetes, Metabolism and Endocrinology, Intercontinental and Japan, and Senior Medical Director, Diabetes and Cardiometabolic Medicine of Lilly Research Laboratories.

Board of Directors

Ron Erickson

Previously Chairman and CEO of eCharge Corporation, Chairman and Co-founder of Blue Frog Mobile, Chairman and CEO of GlobalTel Resources, and Chairman and CEO of Egghead Software.

Jon Pepper
Previously Partner and Owner at Pepcom, Inc., the leader in technology showcase events. Previously founded Digital Focus newsletter, former technology journalist and columnist whose work appeared in The New York Times, Fortune, PC Magazine, and other publications.


William Owens
Executive Chairman at Red Bison Advisory Group, former Chairman of Century Link Telecom, and former Vice Chairman, US Joint Chiefs of Staff.


Ichiro Takesako
President of M2M Technologies, Inc. and At Signal, Inc. and General Manager of Business Development at Sumitomo Precision Products Co., Ltd.

Advisory Board

The Advisory Board will provide guidance to the management team as they accelerate progress toward the FDA clearance process for the world’s first non-invasive glucose monitoring medical devices. Their insights and experience will be invaluable.

James Anderson, MD

Dr. Anderson also serves as Chairman of the Know Labs Medical, Scientific and Regulatory Advisory Board. Current members of the Advisory Board include:       

Larry Ellingson
Mr. Ellingson is the current Vice Chair of the Board of the Diabetes Leadership Council. He is the former Chairman of the American Diabetes Association and has served on several boards, including the European Association for the Study of Diabetes, International Diabetes Federation, and Academy of Nutrition and Dietetics. He began his career and spent 30 years at Eli Lilly and Company, serving as Executive Director of Diabetes Care until his retirement.

Donna Ryan, RN, RD, MPH, CDE
Ms. Ryan is the former President of the American Association of Diabetes Educators. Ms. Ryan brings twenty years of experience in diabetes education and management. She currently serves as Regional Director of Population Health for Ascension Sacred Heart Health System and manages four diabetes outpatient and inpatient programs within Ascension Health. 

Benjamin Smarr, PhD

Dr. Smarr is an assistant professor at the Halicioğlu Data Science Institute and the Department of Bioengineering at the University of California, San Diego. His research has focused on unlocking the potential of continuous physiological data generated from wearables and related technologies for women’s health, education outcomes, long-term care and monitoring in illness of diverse populations.

Jessica Zendler, PhD

Dr. Zendler is a Special Consultant at Rimkus and Adjunct Research Assistant Professor in the School of Kinesiology at the University of Michigan. Her work is focused on understanding the role of movement in injury, physical performance and health, and the use of wearable technology to monitor athletes.

 

Carl Johan Sundberg, MD, PhD

Dr. Sundberg is a licensed physician and Professor of Exercise Physiology at Karolinska Institute in Sweden and Head of the Department of Learning, Informatics, Management and Ethics. His research is focused on human genetics, genomics and epigenetics in relation to exercise in elite athletes, in non-athlete populations, and in patients (cardiovascular, diabetes, psychiatry, oncology).

Mark Aloia, PhD
Dr. Aloia is the current Head of Sleep and Behavioral Science at Sleep Number, overseeing sleep science research, partnerships, and collaborations with the world’s leading physicians, researchers and institutions. He’s also held roles with Philips Respironics, been on the faculty at the University of Rochester and at Brown University and serves as an Associate Professor in the Section of Sleep Medicine and Department of Medicine at National Jewish Health.

Corporate Governance

The Company is committed to excellence with its technology, its product development and the requirements of operating a public company in today’s environment. The senior managers are supported in those efforts by the Know Labs Board of Directors and by their professional service providers. The best place to obtain a comprehensive review of the management and board’s governance is from the Company’s filings with the Securities and Exchange Commission. 

Company

Presentation

Privacy
Policy

Audit
Committee

SEC
Fillings

Terms of
Service

Compensation
Committee

Investor
Information

Code of
Ethics

Nominating &

Governance

Annual Reports, Form 10-K

- FY2022 

- FY2021 

- FY2020 

- FY2019 

Annual Meeting of Shareholders

FY2022 

- DEF 14A Proxy Statements

- Additional Materials

FY2021 

Events and Presentations

Q3 FY2023 Earnings Call
August 14, 2023

00:00 / 43:17

Q2 FY2023 Earnings Call
May 15, 2023 

00:00 / 39:07

American Association of Clinical Endocrinology Annual Meeting 
May 5, 2023

American Physiology Summit 
April 21, 2023

Q1 FY2023 Earnings Call
February 14, 2023 1:30pm PST

00:00 / 23:20

FY2022 Earnings Call
December 20, 2022 1:30pm PST

00:00 / 13:01

2nd Annual Bernstein CGM Disruptors Conference
November 18, 2022

Events

We hope you will join us on this quest.

bottom of page